R&D is a starting point of drug development, commercialization and a locomotive in realizing continuous growth.

To keep our pride of R&D-based biopharmaceutical company, Medytox invests more than 15% of the total sales in R&D – Especially with Gwanggyo R&D Center, established with an one-stop system to conduct all drug development processes except for clinical trial, we are developing biopharmaceuticals that will pioneer the global market.